IP Library Granted Patent US 8,946,222
Granted Patent B2
US 8,946,222 · App. 13/722,595 · Granted Feb 3, 2015

Phenoxymethyl heterocyclic compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,946,222
App. No.
13/722,595
Granted
Feb 3, 2015
Kind
B2
Abstract

Phenoxymethyl compounds that inhibit at least one phosphodiesterase 10 are described as are pharmaceutical compositions containing such compounds an methods for treating various CNS disorders by administering such compounds to a patient in need thereof.

Claims (12)

1. A method for treating a central nervous system (CNS) disorder selected from the group consisting of Huntington's disease, schizophrenia, a schizo-affective condition, obsessive compulsive disorder and psychosis associated with Parkinson's disease, the method comprising administering to a human in need thereof a therapeutically effective amount of 4-(4-(imidazo[1,2-b]pyridazin-2-ylmethoxy)phenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2H)-one or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the CNS disorder is psychosis associated with Parkinson's disease.

3. The method of claim 1 , wherein the CNS disorder is schizophrenia or schizo-affective condition.

4. The method of claim 1 , wherein the CNS disorder is Huntington's disease.

5. The method of claim 1 , wherein the CNS disorder is obsessive compulsive disorder.

6. A method for treating a CNS disorder selected from the group consisting of Huntington's disease, schizophrenia, a schizo-affective condition, obsessive compulsive disorder and psychosis associated with Parkinson's disease, the method comprising administering to a human in need thereof a therapeutically effective amount of a pharmaceutical composition comprising:

(i) 4-(4-(imidazo[1,2-b]pyridazin-2-ylmethoxy)phenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2H)-one or a pharmaceutically acceptable salt thereof; and

(ii) a pharmaceutically acceptable carrier or excipient.

7. The method of claim 6 , wherein the CNS disorder is psychosis associated with Parkinson's disease.

8. The method of claim 6 , wherein the CNS disorder is schizophrenia or schizo-affective condition.

9. The method of claim 6 , wherein the CNS disorder is Huntington's disease.

10. The method of claim 6 , wherein the CNS disorder is obsessive compulsive disorder.

Assignments (3)
SECURITY INTEREST Recorded Jul 5, 2016
From: FORUM PHARMACEUTICALS INC.
To: FMR LLC
Reel/Frame 039254/0828 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2014
From: RIPKA, AMY; SHAPIRO, GIDEON; CHESWORTH, RICHARD
To: ENVIVO PHARMACEUTICALS, INC.
Reel/Frame 033017/0099 →
CHANGE OF NAME Recorded Jun 3, 2014
From: ENVIVO PHARMACEUTICALS, INC.
To: FORUM PHARMACEUTICALS INC.
Reel/Frame 033080/0454 →